Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/2/2024 | $9.00 → $3.00 | Neutral → Underweight | Piper Sandler |
| 7/10/2024 | $8.00 | Mkt Perform | Raymond James |
| 9/20/2023 | $9.00 → $16.00 | Hold → Buy | Jefferies |
| 6/16/2023 | Outperform → Market Perform | TD Cowen | |
| 7/29/2022 | Buy → Hold | Truist | |
| 7/29/2022 | $12.00 → $5.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/28/2022 | Overweight → Neutral | JP Morgan | |
| 6/13/2022 | $12.00 | Overweight | JP Morgan |
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program.We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Assoc
LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is
LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support t
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
8-K - Bausch Health Companies Inc. (0000885590) (Filer)
SD - Bausch Health Companies Inc. (0000885590) (Filer)
Piper Sandler downgraded Bausch Health from Neutral to Underweight and set a new price target of $3.00 from $9.00 previously
Raymond James initiated coverage of Bausch Health with a rating of Mkt Perform and set a new price target of $8.00
Jefferies upgraded Bausch Health from Hold to Buy and set a new price target of $16.00 from $9.00 previously
Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $909 million, up 10%Raising full-year 2024 guidance LAVAL, QC / ACCESSWIRE / October 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2024 financial results and other key updates fro
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.Conference Call DetailsDate:Wednesday, October 30, 2024Time:5:00 p.m. U.S. ESTWebcast:https://ir.bauschhealth.com/events-and-presentationsA replay of the conference call will be available on the investor relations website.To participate in t
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter."We continued our momentum in the second quarter, delivering our fifth
SC 13G - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13D/A - Bausch Health Companies Inc. (0000885590) (Subject)
SC 13G/A - Bausch Health Companies Inc. (0000885590) (Subject)
LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching lives.Jonathan brings a wealth of experience and a proven track record of success both as a physician-scientist and a leader in the pharmaceutical industry. With over 20 years of expertise in clinical research and drug development, he has consistently demonstrated the ability to drive growth and foster innovation. Most recently, at Bristol-Meyers Squibb,
LAVAL, QC / ACCESSWIRE / July 19, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the appointment of two new members to its Executive Leadership Team (ELT).Jean-Jacques Charhon ("JJ") will join the Company as Chief Financial Officer on August 19, 2024. JJ has over 25 years of experience in financial leadership roles with public and private companies across healthcare, high tech and services, primarily at General Electric, Hewlett Packard, Novartis and Purdue Pharma. Upon JJ's arrival, John Barresi, the Company's Interim Chief Financial Officer, will resume his role as SVP, Controller.Aimee Lenar joined the Company on July 15, 2024 as Executive Vice President, US Pharm
BRIDGEWATER, NJ / ACCESSWIRE / December 5, 2023 / Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day. OIC Awareness Day aims to bring awareness to an often-overlooked side effect of opioids. This day will help patients suffering from OIC by breaking down the stigma and silence surrounding this condition."OIC Awareness Day will help bridge the gap between healthcare providers (HCPs), patients, and caregivers by providing
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)
4 - Bausch Health Companies Inc. (0000885590) (Issuer)